Skip to main content

Table 2 Adverse events

From: Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer

  nab-PTX plus RAM PTX plus RAM P value
(N = 113) (N = 138)
  Any grade (%) >Grade 3 (%) Any grade (%) >Grade 3 (%) Any grade >Grade 3
All adverse events 112 (99.1) 76 (67.3) 134 (97.1) 88 (63.8) 0.254 0.563
Hematological
 Neutropenia 91 (80.5) 64 (56.6) 108 (78.3) 76 (55.1) 0.659 0.804
 Leukopenia 85 (75.2) 34 (30.1) 107 (77.5) 48 (34.8) 0.667 0.43
 Anemia 105 (92.9) 8 (7.1) 112 (81.2) 19 (13.8) 0.007 0.089
 Thrombocytopenia 43 (38.1) 6 (5.3) 35 (25.4) 4 (2.9) 0.031 0.258
Non-hematological
 Sensory neuropathy 72 (63.7) 2 (1.8) 51 (37.0) 0 (0.0) 0 0.202
 Fatigue 42 (37.2) 1 (0.9) 33 (23.9) 0 (0.0) 0.022 0.45
 Anorexia 33 (29.2) 1 (0.9) 29 (21.0) 1 (0.7) 0.134 0.699
 Nausea 17 (15.0) 2 (1.8) 18 (13.0) 1 (0.7) 0.649 0.425
 Diarrhea 7 (6.2) 0 (0.0) 14 (10.1) 0 (0.0) 0.261
 Stomatitis 10 (8.8) 0 (0.0) 14 (10.1) 1 (0.7) 0.728 0.55
 Edema 33 (29.2) 0 (0.0) 32 (23.2) 0 (0.0) 0.279
 Proteinuria 30 (26.5) 3 (2.7) 29 (21.0) 2 (1.4) 0.304 0.406
 Hypertension 30 (26.5) 15 (13.3) 27 (19.6) 9 (6.5) 0.189 0.07
 Febrile neutropenia 6 (5.1) 6 (5.1) 13 (9.4) 13 (9.4) 0.221 0.221
 Interstitial pneumonia 8 (7.1) 3 (2.7) 5 (3.6) 3 (2.2) 0.219 0.56
 Hypersensitivity reaction 0 (0.0) 0 (0.0) 2 (1.4) 2 (1.4)
  1. nab-PTX nanoparticle albumin-bound paclitaxel, RAM ramucirumab
\